Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells $324,499.56 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC) insider Fouad Namouni sold 3,633 shares of the stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total value of $324,499.56. Following the completion of the sale, the insider now owns 69,070 shares of the company’s stock, valued at approximately $6,169,332.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Blueprint Medicines Stock Up 0.6 %

Shares of NASDAQ:BPMC opened at $88.61 on Monday. The company’s fifty day moving average is $92.59 and its two-hundred day moving average is $99.04. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.65 and a current ratio of 3.71. Blueprint Medicines Co. has a 1-year low of $43.89 and a 1-year high of $121.90. The stock has a market capitalization of $5.55 billion, a price-to-earnings ratio of -18.42 and a beta of 0.58.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.49. Blueprint Medicines had a negative net margin of 56.64% and a negative return on equity of 157.30%. The firm had revenue of $138.20 million for the quarter, compared to analyst estimates of $104.02 million. During the same quarter in the prior year, the business earned ($2.19) earnings per share. Blueprint Medicines’s quarterly revenue was up 139.9% on a year-over-year basis. Equities analysts anticipate that Blueprint Medicines Co. will post -3.99 EPS for the current year.

Institutional Trading of Blueprint Medicines

A number of institutional investors and hedge funds have recently made changes to their positions in BPMC. Triad Wealth Partners LLC bought a new position in Blueprint Medicines during the 2nd quarter worth $27,000. Covestor Ltd grew its position in shares of Blueprint Medicines by 9,700.0% during the first quarter. Covestor Ltd now owns 294 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 291 shares during the last quarter. Headlands Technologies LLC increased its holdings in shares of Blueprint Medicines by 105.2% in the 1st quarter. Headlands Technologies LLC now owns 667 shares of the biotechnology company’s stock worth $63,000 after acquiring an additional 342 shares during the period. Natixis bought a new stake in Blueprint Medicines in the 1st quarter valued at about $73,000. Finally, CWM LLC boosted its stake in Blueprint Medicines by 114.6% during the 2nd quarter. CWM LLC now owns 1,105 shares of the biotechnology company’s stock valued at $119,000 after purchasing an additional 590 shares during the period.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on BPMC. Needham & Company LLC restated a “buy” rating and issued a $130.00 price target on shares of Blueprint Medicines in a report on Thursday, August 1st. Robert W. Baird raised their price target on shares of Blueprint Medicines from $112.00 to $127.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Oppenheimer lifted their price target on shares of Blueprint Medicines from $114.00 to $125.00 and gave the stock an “outperform” rating in a research note on Monday, July 8th. Guggenheim upped their price objective on shares of Blueprint Medicines from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Finally, Baird R W upgraded Blueprint Medicines to a “strong-buy” rating in a research note on Friday, August 2nd. One research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $120.00.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.